Login
Navigate Fool.com
Will BAYRY beat
the market?

Bayer AG (ADR)

NASDAQOTH: BAYRY

Community Rating: 4 Stars: Favorite

128.54 1.70 (1.34%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $128.10
Previous Close $126.84
Daily Range $127.32 - $128.88
52-Week Range $100.51 - $142.75
Market Cap $106.3B
P/E Ratio 704.67
Dividend (Yield) $0.00 (1.7%)
Volume 77,503
Average Daily Volume 45,330
Current FY EPS $8.39

How do you think BAYRY
will perform against the market?

Top BAYRY Bull/Bear Pitches

 

NetscribePhrmtcl (< 20)
Submitted January 31, 2007

Bayer AG, which created aspirin, is involved worldwide in the discovery, development and marketing of several essential healthcare products, agricultural products for crop protection and animal health … More

1 Replies Reply Report this Post
 

TRGoodvsEvil (< 20)
Submitted July 4, 2009

This portfolio tracks the performance of good vs. evil companies. Evil attributes: -4th largest toxic polluter in the world (http://www.peri.umass.edu/toxic100_index/) -Inventor of mustard gas and he … More

0 Replies Reply Report this Post

News & Commentary

Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?

Last week saw a widespread downturn among biotech stocks. Regeneron Pharmaceuticals, however, was able to move modestly higher. Why?

5 Biotechs With Prostate Cancer Treatments Worth Watching

Prostate cancer is now the second leading cause of cancer-specific deaths among men in the United States. Here are five biotechs aiming to meet this challenge with a diversity of promising new therapies.

Will Biogen Idec Inc. Rule Biotech in 2014?

Off the laurels of its success with Tecfidera, Biogen hits another success with its latest FDA approval.

Is Your Portfolio Exposed to Corruption Risk?

Shareholders in multinational companies like Siemens and Wal-Mart have been hit hard by unexpected corruption charges. Consider whether you might be at risk, too.

1 Piece of News That Could Move Exelixis

Data from Exelixis (EXEL) phase 3 trial of Cometriq in prostate cancer should be released soon. If results are positive, Johnson & Johnson (JNJ), Medivation (MDVN), and Bayer (BAYRY) may face a new competitor.

3 Upcoming FDA Meetings You Should be Watching

With three FDA panel meetings to close out the month investors should have their eyes on these three companies.

Can These Companies Bounce Back from Disappointing Sales?

Promising blood thinner Eliquis hasn't quite lived up to the hype surrounding it in its early life. Can Pfizer and Bristol-Myers Squibb turn things around?

Why Pfizer Investors Should Watch Quark This Summer

A read out on a mid stage trial this summer may offer clues as to whether Pfizer (PFE) may someday have a competitor to Novartis (NVS) and Regeneron (REGN)

5 Big Pharma Stocks With the Strongest Ties to Emerging Markets

Since emerging markets usually offer the best growth prospects, these five big pharmas have devoted the biggest percentage of their sales to these regions.

Bargain Stocks In Europe’s Strongest Economy

See More BAYRY News...

Sector

Healthcare

Industry

Pharmaceuticals

Bayer AG (ADR) (BAYRY) Description

The Company offers products, including ethical pharmaceuticals and other health care products, agricultural products and polymers. Website:

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks